

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

宜昌東陽光長江藥業股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 01558)

**POLL RESULT OF THE EXTRAORDINARY GENERAL MEETING
HELD ON 28 APRIL 2017**

We refer to the circular of YiChang HEC ChangJiang Pharmaceutical Co., Ltd. (the “**Company**”) dated 24 March 2017 (the “**Circular**”) in relation to, among other things, the proposed connected transaction under the Projects Contracting Agreement entered into between the Company and Yidu Shanchengshuidu Project Construction Co., Ltd. (the “**Yidu Construction**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Circular.

EGM

The EGM was held at Conference Room, 4/F, Administration Building, Dongyangguang Scientific Park, No. 5 Shangsha Industrial Zone, Chang’an County, Dongguan, Guangdong Province, the PRC at 10:00 a.m. on Friday, 28 April 2017. The EGM was convened legally and effectively in accordance with the requirements of the Company Law of the PRC and other relevant laws and regulations of the PRC, the Listing Rules and the Articles of Associations.

As at the date of the EGM, the total number of issued shares of the Company was 452,022,850 Shares, of which 226,200,000 were Domestic Shares and 225,822,850 were H Shares. HEC Pharm Co., Ltd.* (宜昌東陽光藥業股份有限公司) (the “**Parent Company**”), who held 226,200,000 issued shares of the Company, was required to abstain and had abstained from voting on the proposed ordinary resolution (the “**Resolution**”) in relation to the proposed connected transaction under the Projects Contracting Agreement at the EGM, as the Parent Company had a material interest in the proposed connected transaction under the Projects Contracting Agreement. Save as disclosed herein, no other Shareholder was required under the Listing Rules

* For identification purpose only

to abstain from voting at the EGM. Accordingly, there were 225,822,850 shares of the Company, representing approximately 49.96% of the total number of the issued shares of the Company, entitling the Shareholders to attend and vote on the Resolution at the EGM. Shareholders holding an aggregate of 81,851,153 shares with voting rights, representing approximately 18.11% of the total number of the issued shares of the Company, attended the EGM either in person or by proxy.

There was no share entitling the holder to attend the EGM and abstain from voting in favour of any of the Resolution under Rule 13.40 of the Listing Rules. No Shareholder has stated the intention in the Circular to vote against or to abstain from voting on the Resolution. The Resolution was voted by way of poll. Computershare Hong Kong Investor Services Limited, the H Share registrar of the Company, acted as the scrutineer for vote-taking at the EGM. Two representatives from the Shareholders and one supervisor of the Company were also the scrutineers for the vote-taking and vote-tabulation.

The poll result in respect of the Resolution was as follow:

ORDINARY RESOLUTION	NUMBER OF VOTES AND PERCENTAGE OF TOTAL VOTING SHARES		
	FOR	AGAINST	ABSTAIN
1. To consider and approve the proposed connected transaction under the Projects Contracting Agreement entered into between the Company and Yidu Construction	81,851,153 (100%)	0 (0%)	0 (0%)

As more than half of the votes were cast in favour of the Resolution above, the ordinary resolution above was duly passed.

On behalf of the Board
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.
TANG Xinfa
Chairman

Hubei, the PRC
28 April 2017

As at the date of this announcement, the executive directors of the Company are Mr. JIANG Juncai, Mr. WANG Danjin and Mr. CHEN Yangui; the non-executive directors of the Company are Mr. TANG Xinfa, Mr. ZHU Yingwei and Mr. MO Kit; and the independent non-executive directors of the Company are Mr. TANG Jianxin, Mr. FU Hailiang and Mr. LEE Chi Ming.